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INTRODUCTION
The use of peripheral blood progenitor cells (PBPCs)
collected after treatment of patients with chemotherapy or
growth factors has become a standard practice for patients
undergoing autologous transplantation. The use of autolo-
gous PBPCs leads to faster engraftment, less early morbidity,
and shorter hospitalization compared with autologous bone
marrow (BM) transplantations [1]. More recently, PBPCs
collected from normal donors after granulocyte colony-
stimulating factor (G-CSF) administration have been used to
reduce the early toxicity of allogeneic transplantation. Sin-
gle-center studies have suggested that neutrophil and platelet
engraftment after such allogeneic PBPC transplantations
may be faster compared with that of historical control sub-
jects who received allogeneic BM [2-5]. Some reports, how-
ever, have indicated that more allogeneic PBPC recipients
experience graft-versus-host disease (GVHD), possibly
because such PBPC harvests contain approximately 10-fold
more T lymphocytes than BM [6,7]. Ongoing randomized
studies comparing allogeneic PBPC and BM transplants will
more deﬁnitively address the relative risk of GVHD associ-
ated with these 2 progenitor cell sources [8,9].
Treatment of donors with growth factors such as G-CSF
followed by PBPC collection may hasten engraftment
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ABSTRACT
We studied whether a short course of granulocyte colony-stimulating factor (G-CSF) administered to normal
donors immediately before bone marrow (BM) harvest would shorten time to neutrophil and platelet engraftment
in matched related allogeneic BM recipients. Twenty-nine normal donors received 4 consecutive daily subcuta-
neous injections of G-CSF (median dose, 12.1 µg/kg per day; range, 9.6-15.7 µg/kg per day) immediately before
BM harvest. Donors tolerated G-CSF well, with only mild myalgias and arthralgias, and BM was easy to aspirate.
The BM harvest contained a median of 5.3  108 white blood cells (WBCs)/kg (range, 3.1-11.1  108 WBCs/kg)
and 2.5  106 CD34+ cells per kg (range, 1.5-7.3  106 CD34+ cells per kg). Median times to neutrophil (18 days
[range, 11-30 days] versus 22 days [range, 16-36 days]; P = .05) and platelet (22 days [range, 15-55 days] versus 27
days [range, 18-46 days]; P = .04) engraftment were statistically shorter than those of historical control subjects
whose donors had not received G-CSF before BM harvest. However, secondary engraftment-dependent outcomes
including red blood cell and platelet transfusions, febrile days, days on antibiotics, days from transplant to hospital
discharge, and days in hospital during the first 60 days after transplant were not statistically different from histori-
cal control subjects. We conclude that G-CSF administered to normal donors immediately before harvest facilitates
BM aspiration, increases the WBC content of the harvest, and hastens neutrophil and platelet engraftment com-
pared with historical control subjects.
KEY WORDS
G-CSF • Aspiration • Engraftment
Biology of Blood and Marrow Transplantation 6:422-427 (2000)
© 2000 American Society for Blood and Marrow Transplantation ASBMT
S.C. was a recipient of a National Cancer Institute of Canada Terry Fox
Postdoctoral Fellowship.
G-CSF Mobilization in Related Allogeneic Marrow Transplantation
423B B & M T
through quantitative and qualitative effects of the growth
factors on progenitor cells. Faster engraftment may be
solely a quantitative effect, since G-CSF–mobilized PBPC
harvests contain more CD34+ cells than unstimulated BM
harvests. In addition, G-CSF may also activate quiescent
progenitors, hasten their maturation, or both, leading to
faster engraftment through qualitative changes in the cellu-
lar composition of the harvest.
Before routinely adopting G-CSF–mobilized PBPCs for
allogeneic transplantation, we studied whether G-CSF
directly increases the progenitor cell content and engraft-
ment potential of normal BM. We postulated that treatment
of normal donors with G-CSF may improve the quantity
and quality of progenitor cells harvested from BM, resulting
in more rapid engraftment, without the additional T lym-
phocytes collected in a PBPC harvest. We report the
engraftment times, incidence of GVHD, and overall survival
of 29 recipients of related allogeneic transplants from
donors who received G-CSF before BM donation.
PATIENTS AND METHODS
Patients
Between April 1997 and September 1998, patients who
had hematologic malignancies and were eligible for matched
related allogeneic transplantation at the Princess Margaret
Hospital (PMH) and Queen Elizabeth II Health Sciences
Centre (QEII HSC) were invited to participate in this study.
Patients eligible for the Canadian Bone Marrow Transplant
Group study (CBMTG 96-01) comparing BM and PBPC in
patients undergoing allogeneic transplantation for myeloid
malignancies [9] were not eligible for this study. The study
was approved by the Institutional Review Boards of the
University of Toronto and the QEII HSC, and all patients
and donors gave informed consent before enrollment.
BM Donors and Harvest
BM donors were ﬁrst-degree relatives of the recipients,
matched at 5 of 6 (2 donors) or all 6 (27 donors) HLA loci.
Donors received 4 daily subcutaneous G-CSF injections
immediately before BM harvest, according to their actual
body weight (<60 kg: 600 µg/day; 60-90 kg: 960 µg/day;
>90 kg: 1200 µg/day). This regimen of moderate-dose (median
12.1 µg/kg per day), short-course G-CSF was used to minimize
the exposure of normal donors to this growth factor [5]. BM
was collected from the posterior iliac crests as described [10].
The BM harvest was completed when a minimum of 3 
108 white blood cells (WBCs)/kg recipient weight, but not
more than 22 mL BM per kg donor weight, was collected.
Preparative Regimen and Supportive Care
Recipients were conditioned using chemotherapy with or
without radiation according to each recipient’s diagnosis and
disease status (Table 1) and nursed in single, laminar-flow
and/or positive-pressure, high-efficiency particulate air
(HEPA)-ﬁltered rooms. At 1 center (PMH), posttransplanta-
tion prophylactic antibiotics (trimethoprim-sulfamethoxasole
or ciproﬂoxacin) were administered orally until the patient
could no longer swallow. Antifungal prophylaxis and growth
factors posttransplantation were not used. Patients who were
seropositive for herpes simplex virus received acyclovir (400
mg by mouth twice a day or 80 mg intravenously [IV] twice a
day) from day 1 until day 28. Broad-spectrum antibiotics were
administered when neutropenic patients (absolute neutrophil
count [ANC] <0.5  109/L) became febrile. Irradiated platelet
transfusions were routinely given when the morning platelet
count was <10  109/L, and irradiated red blood cells were
transfused when the hemoglobin concentration was <80 g/L.
All patients received cyclosporine (6.25 mg/kg by mouth
twice a day or 2.5 mg/kg IV twice a day) from day –1, and
the dose was adjusted to maintain a trough whole blood
cyclosporine level of 200 to 400 µg/L. Methotrexate was
administered IV on day 1 (15 mg/m2) and days 3, 6, and 11
(10 mg/m2), with dose reductions for mucositis (Bearman
grades 2 and 3), decreased calculated creatinine clearance,
and direct hyperbilirubinemia as required. Patients at risk for
cytomegalovirus (CMV) disease underwent bronchoscopy
with bronchoalveolar lavage (BAL) on day 35 (PMH) or days
35 and 49 (QEII HSC) and were treated with ganciclovir if
the BAL shell vial culture was positive for CMV. 
Evaluations and Definitions
The WBC count and CD34+, CD3+, and colony-forming
unit (CFU) (granulocyte/macrophage [CFU-GM], multipo-
tential [CFU-GEMM], burst-forming unit-erythroid
[BFU-E], and megakaryocyte [CFU-Mega]) cell counts of
BM harvests were assayed on the day of collection. CFU cell
counts of the donors’ BM were also assayed before starting
treatment with G-CSF. WBC counts were measured using
an automated counter (Coulter, Hialeah, FL) and verified
visually. CD34+ cells were quantified according to the
method of Sutherland et al. [11]. CD3+ cells were measured
by ﬂow cytometry using monoclonal antibodies recognizing
CD3+ and CD45+ cell surface antigens and a FACSort
Table 1. Preparative Regimens According to Diagnosis and Disease Status
Diagnosis Preparative Regimen
Chronic myeloid leukemia (first chronic phase), (1) Intravenous cytarabine 100 mg/m2 per day by continuous infusion × 5 days
acute myeloid leukemia (first complete remission) followed by intravenous cyclophosphamide 60 mg/kg per day × 2 days and 500 cGy
single-fraction total body irradiation (TBI) or (2) busulfan 1 mg/kg by mouth every 
6 h × 16 doses followed by intravenous cyclophosphamide 60 mg/kg per day × 2 days
Chronic myeloid leukemia (beyond first chronic (1) Intravenous cyclophosphamide 60 mg/kg per day × 2 days followed by 1200 cGy
phase), acute myeloid leukemia (beyond first fractionated TBI (200 cGy twice a day × 3 days) or (2) busulfan 1 mg/kg by mouth every
complete remission), myelodysplastic syndrome 6 h × 16 doses followed by intravenous cyclophosphamide 60 mg/kg per day × 2 days
Acute lymphoid leukemia, non-Hodgkin’s lymphoma, Busulfan 1 mg/kg by mouth every 6 h × 16 doses followed by intravenous
multiple myeloma, chronic lymphocytic leukemia cyclophosphamide 60 mg/kg per day × 2 days
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instrument (Becton Dickinson, Franklin Lakes, NJ). CFU
progenitor cell assays were performed as described [10].
Day of neutrophil engraftment was deﬁned as the second
of 2 days with an ANC >0.5  109/L, and day of platelet
engraftment was defined as the second of 2 days with a
platelet count >20  109/L independent of platelet transfu-
sion. Duration of ﬁrst hospitalization was measured from the
day of BM infusion until the day of ﬁrst hospital discharge.
GVHD was graded according to published criteria [12,13].
Patients who experienced neutrophil engraftment and sur-
vived until at least day 30 posttransplantation were assessed
for acute GVHD. Patients who survived until at least day
100 posttransplantation were assessed for chronic GVHD.
Statistical Methods
Descriptive statistics (median and range) were used to
describe donor, recipient, and BM characteristics. Times to
neutrophil and platelet engraftment and secondary engraft-
ment-dependent outcomes were compared with historical
control subjects using the Kruskal-Wallis rank sum test.
Correlation analyses were performed using the Spearman
rank test.
RESULTS
BM Donors and Harvest Characteristics
BM donors tolerated G-CSF injections with only mild
myalgias and arthralgias. No donor experienced evidence of
leukostasis or abnormal bleeding. BM donors who received
G-CSF have been followed for at least 2 years and have not
had any long-term adverse effects. Donor and BM harvest
characteristics are shown in Table 2. BM was consistently
very easy to aspirate during the harvest, as indicated by the
short median BM harvest duration. There was no signiﬁcant
correlation between donor age or sex and BM characteristics.
The CFU cell counts of the BM harvests after G-CSF
administration were similar to those before G-CSF adminis-
tration (Table 2) and lower than those of historical control
subjects who had not received G-CSF before BM harvest [5].
Recipients
Twenty-nine patients received allogeneic BM from
related donors who were matched for 5 of 6 or 6 of 6 HLA
antigens and who had received G-CSF. Patient characteris-
tics are shown in Table 3. The allogeneic BM infusion was
well tolerated. Neutrophil engraftment occurred in 27 of 29
(93%) recipients; 2 died before neutrophil engraftment.
Platelet engraftment occurred in 24 of 29 (83%) recipients; 5
died before platelet engraftment. Times to neutrophil and
platelet engraftment and secondary engraftment-dependent
outcomes are shown in Table 3. The times to neutrophil and
platelet engraftment were signiﬁcantly faster compared with
those of historical control subjects who received unstimu-
lated BM at our institutions [5]; time to neutrophil engraft-
ment was 18 days (range, 11-30 days) versus 22 days (range,
16-36 days), P = .05; time to platelet engraftment was
22 days (range, 15-55 days) versus 27 days (range, 18-46
days), P = .04. However, secondary engraftment-dependent
Table 2. Donor and Harvest Characteristics*
G-CSF-Stimulated BM Unstimulated BM (Historical Control Subjects)
n 29 20
Donor age, y 48 (18-73) 52 (20-68)
Donor sex, M/F 18/11 12/8
Daily G-CSF dose, g/kg per day 12.1 (9.6-15.7) —
BM harvest duration, min 34 (10-80) 67 (50-95)
BM harvest volume, mL 950 (620-1950) 1000 (500-1300)
WBCs/kg recipient weight 5.3 × 108 (3.1-11.1 × 108) 3.13 × 108 (1.6-4.2 × 108)
CD34+/kg recipient weight 2.5 × 106 (1.5-7.3 × 106) NA
CD3+/kg recipient weight 1.6 × 107 [0.4-3.5 × 107 (n = 21)] NA
CFU cell content before G-CSF administration†
CFU-GM/kg recipient weight, 104 18 (2-59) 65 (31-183)
CFU-GEMM/kg recipient weight, 104 0.17 (0.09-0.3) 4.4 (1.5-14.4)
BFU-E/kg recipient weight, 104 21 (3-58) 119 (23.7-331)
CFU-Mega/kg recipient weight, 104 2.9 (0.1-8.4) 14 (1.2-60.3)
CFU cell content after G-CSF administration†
CFU-GM/kg recipient weight, 104 10 (5-15) —
CFU-GEMM/kg recipient weight, 104 0.15 (0.07-0.2) —
BFU-E/kg recipient weight, 104 6 (2-10) —
CFU-Mega/ kg recipient weight, 104 2.6 (0.7-5.0) —
*Data are median (range) or n. G-CSF indicates granulocyte colony-stimulating factor; BM, bone marrow; WBC, white blood cell; NA, not avail-
able; CFU, colony-forming unit; CFU-GM, colony-forming unit-granulocyte/macrophage; CFU-GEMM, multipotential colony-forming unit;
BFU-E, burst-forming unit-erythroid; CFU-Mega, colony-forming unit-megakaryocyte.
†Plating efﬁciency (number of colonies per cell plated) was measured for cells from the normal donor’s bone marrow before G-CSF administration and at
the time of BM harvest. For each colony type (CFU-GM, CFU-GEMM, BFU-E and CFU-Mega), the CFU cell content expressed per kg recipient
weight was calculated as follows:
colony count
×
(WBC concentration of BM harvest)(volume of harvest) .
number of cells plated weight of recipient
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outcomes, including number of platelet and red blood cell
transfusions, number of febrile days, days on antibiotics, days
from BMT to first hospital discharge, and days in hospital
during the ﬁrst 60 days posttransplantation were not statisti-
cally different from those of historical control subjects at our
institutions [5]. In this group of 29 patients, we did not ﬁnd
any signiﬁcant correlation between characteristics of the BM
harvest (WBC, CD34+, and CFU cell content) and times to
neutrophil and platelet engraftment.
GVHD and Survival
Patients received a median of 3.75 doses (range, 2-4 doses)
of a possible maximum of 4 full doses of methotrexate.
Two patients were not assessable for acute GVHD because
of early death. The incidence of acute GVHD (grades I to
IV) was 19 of 27 (70%), and 11 of 27 (41%) patients experi-
enced grades II to IV acute GVHD. As of May 1999, 19 of
29 (65%) patients were alive and had been followed for at
least 6 months. The cumulative incidence of chronic
GVHD among these patients was 5 of 11 (45%), with 4
(36%) and 1 (9%) experiencing limited and extensive
chronic GVHD, respectively. Most patients (4 of 5) with
chronic GVHD required systemic treatment. 
At a median follow-up of 6 months (range, 0.5-17 months),
the 100-day mortality was 6 of 29 (21%) and the 1-year
overall survival of patients followed for at least 1 year was 7
of 17 (41%).
DISCUSSION
Autologous PBPC transplantations result in faster
engraftment, fewer transfusions, shorter hospitalizations,
and less early transplantation morbidity compared with
autologous BM transplantations [1]. Patients also avoid the
potential morbidities of anesthesia and BM harvest. In addi-
tion, PBPC collections may result in more patients proceed-
ing to transplantation, because growth factor–mobilized
PBPC collections contain more progenitors than autologous
BM harvests.
The beneﬁts of allogeneic PBPC transplantations are not
as clearly established. Several studies have reported that they
too hasten engraftment, although the effects reported to date
have been modest [2-5]. Furthermore, allogeneic engraftment
can also be affected by other factors such as the regimen used
for GVHD prophylaxis—in particular, methotrexate. Allo-
geneic PBPC collections also contain approximately 10-fold
more T lymphocytes than BM harvests, which may lead to a
greater risk of GVHD [6,7]. For these reasons, we studied
whether the engraftment of allogeneic BM could be
improved by administering G-CSF to donors before BM
harvest. Because a short G-CSF course dramatically
increases the number of PBPCs, we postulated that adminis-
tering a similar course of G-CSF may also either increase the
number of BM progenitor cells or activate and mature pre-
existing BM progenitor cells. Whereas G-CSF administered
before BM harvest may not offer any advantage over PBPC
collection for patients undergoing autologous transplanta-
tion, it may improve allogeneic BM collection, avoiding the
more plentiful T lymphocytes present in a PBPC harvest.
Johnson et al. [14] studied 22 patients with hematologic
malignancies who received G-CSF, granulocyte-macrophage
CSF (GM-CSF), or interleukin (IL)-3 before autologous
BM harvest and found that each cytokine increased the
number of light-density cells isolated from BM. G-CSF and
GM-CSF also increased the total number of CFU-GM
cells. Engraftment times were not reported. In a similar
study, Slowman et al. [15] administered GM-CSF or G-CSF
before BM harvest to 11 patients with nonhematologic
Table 3. Patient Engraftment and Engraftment-Dependent Characteristics*
G-CSF–Stimulated BM Unstimulated BM (Historical Control Subjects)
n 29 20
Recipient age, y 45 (17-61) 46 (20-58)
Recipient sex, M/F 17/12 12/8
Recipient diagnosis
Chronic myeloid leukemia, first chronic phase 1 4
Chronic myeloid leukemia, relapse after first BMT 2 0
Acute myeloid leukemia, first complete remission 1 2
Acute lymphoid leukemia, first complete remission 7 4
Acute lymphoid leukemia, complete remission 2 or more 2 0
Myelodysplastic syndrome, de novo 4 3
Myelodysplastic syndrome, after autologous BMT 2 0
Non-Hodgkin’s lymphoma, chemosensitive 6 3
Multiple myeloma, chemosensitive 2 2
Chronic lymphocytic leukemia, chemosensitive 2 2
Neutrophil engraftment, d 18 (11-30) (n = 27) 22 (16-36)
Platelet engraftment, d 22 (15-55) (n = 24) 27 (18-46)
Platelet transfusions 4 (1-17) (n = 28) 6 (2-16)
Red blood cell transfusions 4 (0-31) (n = 28) 5 (2-21)
Febrile days, day 0 to first discharge 5 (0-19) 2 (0-17)
Days on antibiotics, day 0 to first discharge 16 (2-63) 16 (0-56)
Days to first discharge 29 (16-67) 29 (21-51)
Days in hospital, day 0 to day 60 34 (14-60) (n = 26) 39 (26-60)
*Data are median (range) or n. G-CSF indicates granulocyte colony-stimulating factor; BM, bone marrow.
S. Couban et al.
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malignancies and found higher nucleated cell and CD34+
cell concentrations compared with concurrent control sub-
jects. Although neutrophil engraftment was faster in the
cytokine-treated group (12 versus 24 days), this group also
received cytokines after infusion, confounding the effect of
cytokines administered before harvest. Lowenthal et al. [16]
administered G-CSF before BM harvest in 15 heavily
pretreated patients and reported prompt engraftment, but
there was no control group for comparison. 
Other investigators have not found faster autologous
engraftment with this strategy. Hansen et al. [17] adminis-
tered G-CSF, GM-CSF, or IL-3 before BM harvest to
37 patients with hematologic diseases and found increased
marrow cellularity, a higher myeloid:erythroid ratio, and
more myeloid progenitors, but engraftment was not faster
compared with that of historical control subjects. Sosman et
al. [18] administered IL-3 before BM harvest to 19 patients
with nonhematologic cancers, and engraftment was not
improved, although the CFU-GM content of the BM was
increased.
Because patients undergoing autologous transplantation
have often received prior chemotherapy, which may have
damaged hematopoietic stem cells in the BM, or have
tumor involvement of the BM, their BM may not respond
well to cytokine-mediated stimulation. Surprisingly, there
have been few reports of cytokines administered to normal
donors before allogeneic BM harvest. Meisenberg et al. [19]
administered G-CSF to 8 normal donors before BM har-
vest and found prompt neutrophil and platelet engraftment,
but G-CSF was also administered after infusion. Isola et al.
[20] described 5 patients whose donors received G-CSF
before BM harvest and reported median neutrophil and
platelet engraftment at 14 and 16 days, respectively, which
was faster than in concurrent control subjects. Finally, in 12
patients also treated with G-CSF [21], a median of 1.6 
106 CD34+ cells per kg was collected from the stimulated
BM, but engraftment times were not reported and the col-
lections were T-cell–depleted, making comparison with
non–T-cell–depleted engraftment difﬁcult.
Our study of 29 patients is the largest reported series
to examine the effect of G-CSF administration to normal
donors before BM harvest. We found that this strategy did
modestly improve times to neutrophil and platelet engraft-
ment compared with those of historical control subjects
who had received unstimulated BM. Although our patient
cohort was similar to the historical control subjects in
terms of age and disease and they received identical
GVHD prophylaxis and supportive care, this was not a
randomized comparison of G-CSF–stimulated BM and
unstimulated BM, and there may have been other differences
between the 2 groups that have not been accounted for. 
In this study, G-CSF was well tolerated, BM was easy to
aspirate, and the median WBC per kg recipient weight of
the harvest was high. However, we did not ﬁnd an improve-
ment in secondary engraftment-dependent outcomes com-
pared with those of historical control subjects. This may be
explained by the small sample size, which limited our ability
to detect differences in secondary outcomes if they were
present. The small size of this study also precluded us from
establishing whether the use of G-CSF–stimulated BM
affects the likelihood of developing GVHD. The incidence
of acute and chronic GVHD was similar to that of recipients
of unstimulated BM at our centers [5,10].
This study indicates the need for further investigation of
the strategy of administering a growth factor before allo-
geneic BM harvest. Administering G-CSF for 4 days imme-
diately before a BM harvest may not be the best way to collect
BM progenitor cells. Although G-CSF is administered in
this way before PBPC collection, the direct effect of G-CSF
on BM may be greater after a different G-CSF dose or a dif-
ferent time interval between G-CSF administration and BM
harvest. In a murine model, Bodine et al. [22] found that the
repopulating ability of BM cells was low immediately after
treatment with G-CSF and stem cell factor but increased
more than 10-fold 14 days later. Whereas G-CSF effectively
facilitates PBPC collections and has been shown in this
study to modestly hasten engraftment after BM transplanta-
tion, BM progenitor cells may be more effectively stimu-
lated by other cytokines or cytokine combinations. Further
studies of other cytokines, cytokine combinations [23,24],
and BM harvest schedules may be indicated, particularly if
allogeneic PBPC transplantations are shown to lead to
unacceptably high rates of GVHD. 
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